gefitinib has been researched along with fingolimod hydrochloride in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 2,771 | 157 | 2,062 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baxter, RC; Boyle, FM; de Silva, HC; Julovi, SM; Lin, MZ; Martin, JL | 1 |
1 other study(ies) available for gefitinib and fingolimod hydrochloride
| Article | Year |
|---|---|
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Topics: Animals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Fingolimod Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Insulin-Like Growth Factor Binding Protein 3; Mice; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |